Gilead and Evoq Therapeutics announce collaboration to advance immunotherapies
Gilead Sciences, Inc. and Evoq Therapeutics, Inc. announced a collaboration and licensing agreement to advance Evoq’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus
Evoq’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilead and EVOQ will collaborate on preclinical development. Gilead has the option to exclusively license rights to Evoq's NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization. Under the terms of the agreement, Evoq could potentially receive up to $658.5 million total in upfront, option exercise and milestone payments across all programs, as well as tiered royalties on product sales.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins